Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

34P - Validation of A New Scoring System for Molecular Subtyping of Gastric Cancer

Date

06 Oct 2021

Session

e-Posters

Presenters

Irina Cazacu

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

I.M. Cazacu1, A. Filippi2, V.M. Croitoru1, S. Kitahara3, A. Matsui3, G. Lauwers3, A. Sorop2, L.G. Necula4, L. Matei4, C. Pechianu2, A.E. Croitoru1, V. Herlea2, A. Saftoiu5, D. Paul6, M. Chivu-Economescu4, S. Dima2, D.G. Duda3, I. Popescu2

Author affiliations

  • 1 Fundeni Clinical Institute, 22328 - Bucharest/RO
  • 2 Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 77085 - Bucharest/RO
  • 3 Massachusetts General Hospital, Boston/US
  • 4 Stefan St. Nicolau Institute of Virology, Bucharest/RO
  • 5 University of Medicine and Pharmacy Craiova, Craiova/RO
  • 6 Weill Cornell Medicine, New York/US
More

Abstract 34P

Background

Molecular classification of gastric cancer may potentially provide tailored treatment options by predicting survival outcomes and patients’ response to therapy. In our prior study by Setia et al. [Modern Patho 29.7 (2016): 772-784], we identified five groups of gastric cancers based on Epstein–Barr virus (EBV) positivity, microsatellite instability (MSI), aberrant E-cadherin, and p53 expression (normal/aberrant). The aim of this study was to validate the association between these molecular subtypes and the prognosis of patients with gastric cancer from Romania.

Methods

The molecular classification was reproduced in a retrospective cohort of 121 resected gastric cancers at Fundeni Clinical Institute, Bucharest. EBER in situ hybridization, p53, microsatellite instability, and E-cadherin expression were analyzed using immunohistochemical, RT-PCR and in situ hybridization techniques.

Results

EBV-positive gastric cancers represented 30% of the cases (n=36); microsatellite instable adenocarcinoma constituted 9% of the cases (n=11); aberrant expression of E-cadherin was identified in 17% (n=20) while aberrant p53 expression was noted in 34% (n=42) of the gastric cancers. The remaining patients with normal p53 expression represent 10% (n=12) of total cases. The MSI high subtype was associated with a significantly more favorable prognosis while gastric cancers with aberrant E-cadherin expression had the least favorable prognosis (log-rank, p=0.001). Patients with EBV cancer subtype had superior median overall survival compared to those with aberrant E-cadherin expression (p=0.04).

Conclusions

The proposed molecular classification successfully stratified patients by survival. Our results demonstrated a trend for superior survival in the MSIhigh subtype and EBV-positive gastric adenocarcinomas. These data warrant further validation of this scoring system and the role of anti-tumor immunity in MSI-high and EBV-positive subtypes.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.